Abstract

BackgroundUbiquitination and ubiquitin-like protein post-translational modifications play an enormous number of roles in cellular processes. These modifications are constituted of multistep reaction cascades. Readily implementable and robust methods to evaluate each step of the overall process, while presently limited, are critical to the understanding and modulation of the reaction sequence at any desired level, both in terms of basic research and potential therapeutic drug discovery and development.ResultsWe developed multiple robust and reliable high-throughput assays to interrogate each of the sequential discrete steps in the reaction cascade leading to protein ubiquitination. As models for the E1 ubiquitin-activating enzyme, the E2 ubiquitin-conjugating enzyme, the E3 ubiquitin ligase, and their ultimate substrate of ubiquitination in a cascade, we examined Uba1, Rad6, Rad18, and proliferating cell nuclear antigen (PCNA), respectively, in reconstituted systems. Identification of inhibitors of this pathway holds promise in cancer therapy since PCNA ubiquitination plays a central role in DNA damage tolerance and resulting mutagenesis. The luminescence-based assays we developed allow for the quantitative determination of the degree of formation of ubiquitin thioester conjugate intermediates with both E1 and E2 proteins, autoubiquitination of the E3 protein involved, and ubiquitination of the final substrate. Thus, all covalent adducts along the cascade can be individually probed. We tested previously identified inhibitors of this ubiquitination cascade, finding generally good correspondence between compound potency trends determined by more traditional low-throughput methods and the present high-throughput ones.ConclusionsThese approaches are readily adaptable to other E1, E2, and E3 systems, and their substrates in both ubiquitination and ubiquitin-like post-translational modification cascades.

Highlights

  • Ubiquitination and ubiquitin-like protein post-translational modifications play an enormous number of roles in cellular processes

  • We found half-maximal inhibitory concentration (IC50) values and structure–activity relationship trends for Uba1 inhibitors we previously reported [19] as determined by the amplified luminescent proximity homogeneous assay (Alpha) assay generally corresponding to other more traditional methods in terms of both inhibition of the overall proliferating cell nuclear antigen (PCNA) ubiquitination cascade and Uba1

  • We investigated the optimal parameters for Alpha detection after the PCNA ubiquitination reaction, looking at different dilution factors (Additional file 2: Fig. S2), donor and acceptor bead concentrations (Additional file 3: Fig. S3a), donor and acceptor bead ratios (Additional file 3: Fig. S3b), order of addition of donor and acceptor beads (Additional file 4: Fig. S4), and bead incubation times prior to detection (Additional file 5: Fig. S5)

Read more

Summary

Introduction

Ubiquitination and ubiquitin-like protein post-translational modifications play an enormous number of roles in cellular processes. These modifications are constituted of multistep reaction cascades. Modulating various steps of ubiquitination and UBL post-translational modification pathways with smallmolecule inhibitors or activators/enhancers has considerable research and therapeutic potential. One such function for ubiquitin and UBLs is in the dynamic control of the DNA damage repair and tolerance machinery. There are two general pathways of DNA damage tolerance: translesion DNA synthesis (TLS) and template switching. DNA damage tolerance can lead to genetic alterations, oncogenesis, formation of secondary tumors after treatment with DNA-damaging therapeutics, drug resistance, and other pathologies, with strong evidence that inhibition of the DNA damage response can lead to reversal of drug resistance in and apoptotic death of a range of different cancer cell types (reviewed in refs. [1,2,3,4,5,6])

Methods
Results
Discussion
Conclusion
Full Text
Paper version not known

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.